Radioisotope Production (Thallium-201)

Tl-201 decays by electron capture and gamma emission with a half-life of 3.04 days. It is typically produced in cyclotrons by bombarding thallium-203 with protons. The resulting Tl-201 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of cyclotrons, thallium targets, and radiochemistry facilities. Logistical challenges include the transport and delivery of Tl-201 radiopharmaceuticals. Accessibility for developing countries is limited by the high cost and technical expertise required for production and handling.

Tl-201 production and application are well-established, with widespread use in nuclear cardiology.

Tl-201 is a radioactive isotope that emits gamma rays, requiring careful handling and shielding to minimise radiation exposure.

While Tl-201 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.

Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of Tl-201 may be considered to ensure transparency and prevent misuse.